Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 1267 (miR-1267) is a small non-coding RNA molecule, part of the microRNA family, which acts as a regulator of gene expression at the post-transcriptional level. It primarily functions by binding to complementary sequences on target mRNA transcripts, leading to translational repression or mRNA degradation, typically as part of the RNA-induced silencing complex (RISC). Limited studies suggest that miR-1267 may play a dual role in breast cancer, acting as a tumor suppressor during early tumor development but potentially promoting invasion and metastasis in later stages. Its altered expression has been observed in several cancers, and it is being investigated as a molecular biomarker for cancer diagnosis and prognosis. Currently, no drugs are known to directly target miR-1267, nor is it directly considered a traditional druggable target, such as a receptor or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 1267 (miR-1267).